ProPhase Labs proposes public stock offering; discloses $500K term note and future receipts deals

ProPhase Labs, Inc.

Announced underwritten public offering of common stock and/or pre-funded warrants; no size or price disclosed.
ThinkEquity sole book-running manager; proceeds earmarked for working capital, product development, and M&A.
Disclosed $500K term note at 15% interest and two future receipts financings aggregating ~$2.1M.
BE-Smart esophageal cancer test faces regulatory uncertainty due to new FDA LDT rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.